Product image of Jakavi (Ruxolitinib) supplied by GNH India

Jakavi

Active Ingredient:
Ruxolitinib
Origin:
EU

Jakavi (Ruxolitinib)

Ruxolitinib, the active ingredient in Jakavi, is a Janus kinase (JAK) inhibitor presented as an oral tablet for oral use. It is indicated for the treatment of primary myelofibrosis, polycythemia vera, and is used off‑label for graft‑versus‑host disease in appropriate patients.
GNH India supplies Jakavi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Novartis Europharm Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Jakavi (ruxolitinib) targets dysregulated JAK‑STAT signaling in myeloproliferative disorders and related conditions.

  • Primary myelofibrosis: reduces spleen size and alleviates disease‑related symptoms.
  • Polycythemia vera: helps control hematocrit levels and decreases need for phlebotomy.
  • Graft‑versus‑host disease (off‑label): may mitigate inflammatory manifestations in affected patients.

How It Works

  • Ruxolitinib selectively inhibits the tyrosine kinase activity of JAK1 and JAK2, thereby blocking cytokine‑mediated signaling pathways that drive abnormal hematopoietic cell proliferation and inflammatory responses. This interruption of the JAK‑STAT cascade reduces disease activity in myeloproliferative neoplasms and related immune‑mediated conditions.

Side Effects

Ruxolitinib may cause a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects

  • Anemia: reduced red blood cell count leading to fatigue.
  • Thrombocytopenia: lowered platelet levels increasing bleeding risk.
  • Diarrhea: loose stools that may affect hydration.

Serious or Rare Side Effects

  • Infections: heightened susceptibility to bacterial, viral, or fungal infections.
  • Reactivation of hepatitis B: potential flare of previously controlled hepatitis B infection.
  • Severe liver injury: marked elevation of liver enzymes or hepatic failure.

Precautions & Warnings

When prescribing Ruxolitinib, clinicians should consider several safety and handling precautions.

  • Monitor blood counts: regular CBC testing to detect anemia, thrombocytopenia, or neutropenia.
  • Assess infection risk: evaluate for active infections before initiation and monitor during therapy.
  • Evaluate liver function: periodic liver enzyme tests are recommended.
  • Avoid use in pregnancy unless benefits outweigh risks: discuss potential fetal effects with a specialist.
  • Review concomitant medications: check for interactions that may alter drug exposure.
  • Store at ambient temperature: keep in the original pack, protect from moisture.

Avoid Interactions

Ruxolitinib can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase ruxolitinib exposure.
  • Strong CYP3A4 inducers (e.g., rifampicin): may reduce therapeutic levels.
  • Live vaccines: risk of uncontrolled infection due to immunosuppression.

Moderate Interactions (Monitor Closely)

  • Anticoagulants (e.g., warfarin): may enhance bleeding tendency.
  • Immunosuppressants (e.g., azathioprine): additive immunosuppression risk.
  • CYP2C9 substrates (e.g., warfarin): potential alteration of plasma concentrations.

Frequently Asked Questions

Jakavi (ruxolitinib) is prescribed for patients with primary myelofibrosis and polycythemia vera to control disease‑related symptoms and blood parameters. It is also employed off‑label for certain cases of graft‑versus‑host disease where cytokine‑driven inflammation is a concern.

Ruxolitinib blocks the activity of Janus kinase 1 and 2 (JAK1/JAK2), key enzymes in the JAK‑STAT signaling pathway. By inhibiting these kinases, the drug reduces abnormal cell proliferation and inflammatory cytokine signaling that underlie myeloproliferative disorders.

The dosage of Jakavi is individualized and determined by the prescribing physician based on the specific indication, patient weight, blood counts, and tolerability. Patients should follow the dose and schedule provided by their healthcare professional.

Safety data for ruxolitinib in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made in consultation with a qualified obstetrician or pediatrician.

To request Jakavi, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Jakavi is a targeted JAK inhibitor, offering a mechanism‑specific approach compared with conventional therapies such as hydroxyurea or interferon. Clinical studies have shown it can more effectively reduce spleen volume and improve symptom burden, though individual response and side‑effect profiles vary.

Jakavi tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the medication out of reach of children and do not use if the packaging is damaged.

Jakavi is taken orally as a tablet, usually with or without food, according to the schedule prescribed by the treating physician. Patients should swallow the tablet whole and avoid crushing or splitting it unless instructed otherwise.

Serious risks include severe infections, reactivation of hepatitis B, and significant liver injury. Patients should promptly report signs of infection, jaundice, or unusual bleeding, and undergo regular monitoring of blood counts and liver function tests.

Jakavi is contraindicated in patients with known hypersensitivity to ruxolitinib or any tablet excipients. It should be used with caution, or avoided, in individuals with active uncontrolled infections, severe hepatic impairment, or in those who are pregnant without a clear benefit‑risk justification.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Ruxolitinib

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT